What were the results of the Heart Protection Study (HPS) trial?
The Heart Protection Study (HPS) compared simvastatin 40 mg daily to placebo in patients with IHD, other occlusive vascular disease, or diabetes mellitus. On-treatment LDL cholesterol levels averaged 88 mg/dL in those allocated to simvastatin and 127 mg/dL in those randomized to placebo. A consistent and early benefit of therapy was demonstrated, with a 13% reduction in mortality rate and an 18% reduction in coronary death rate.398 Similar reductions in RR were observed regardless of baseline levels of LDL cholesterol, including in those with initial levels ,116 mg/dL or ,97 mg/dL.